People with HIV are living longer, thanks to modern medicine, but they still face a higher risk of heart disease. Doctors have long recommended statins—(medication that lowers cholesterol)—to help prevent heart attacks and strokes. Now, new findings from the REPRIEVE trial, presented at the CROI 2025 Conference, show that statins do help.
However, the study also raises a big question: Are doctors using the right tests to find out who needs these drugs the most?
Dr. Steven Grinspoon and his team at Massachusetts General Hospital found that a certain type of hidden artery plaque—called non-calcified plaque (NCP)—might be a better warning sign for heart disease in people with HIV than the standard test that looks for hardened (calcified) plaque.
This finding could change how doctors decide who should take statins and help more people get the treatment they need before a serious heart problem occurs.
Read the full news story at Life4me+.
View all Life4me+ reports from CROI 2025
Source : Life4me+
Related HIV and Co-Infections News
-
New treatment for cryptococcal meningitis enters Phase II trial as global HIV funding cuts threaten to cause a massive increase in advanced HIV disease
-
Molecular stool test could improve detection of TB in adults with HIV
-
Montreal researchers explore different factors affecting brain health and frailty among older people with HIV
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.